Suchergebnisse - "Buti, Maria"

PubPharm (8)

1

Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review

enthalten in: PharmacoEconomics | 2013

von Buti, M. | Oyagüez, I. | Lozano, V. | +1

2

Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B

enthalten in: PharmacoEconomics | 2012

von Buti, M. | Oyagüez, I. | Lozano, V. | +1

3

Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B

enthalten in: PharmacoEconomics | 2012

von Buti, M. | Oyagüez, I. | Lozano, V. | +1

4

Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B

enthalten in: PharmacoEconomics | 2012

von Buti, M. | Oyagüez, I. | Lozano, V. | +1

5

Financial impact of two different ways of evaluating early virological response to peginterferon-α-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1

enthalten in: PharmacoEconomics | 2005

von Buti, M. | Casado, M. | Fosbrook, L. | +1

6

Financial impact of two different ways of evaluating early virological response to peginterferon-α-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1

enthalten in: PharmacoEconomics | 2005

von Buti, M. | Casado, M. | Fosbrook, L. | +1

7

Financial impact of two different ways of evaluating early virological response to peginterferon-α-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1

enthalten in: PharmacoEconomics | 2005

von Buti, M. | Casado, M. | Fosbrook, L. | +1

8

Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1

enthalten in: PharmacoEconomics | 2005

von Buti, M. | Casado, M. | Fosbrook, L. | +1

1
[1]